Skip to main
KYTX

KYTX Stock Forecast & Price Target

KYTX Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kyverna Therapeutics is a clinical-stage biopharmaceutical company that has a promising future due to its innovative cell therapies for autoimmune diseases. With FDA alignment on its single-arm SPS filing, a high probability of approval for its product KYV-101, and a strong clinical and manufacturing package, the company is well-positioned for success. Furthermore, its SPS product has shown significant improvement in disease measures and has the potential for premium pricing, making it a meaningful revenue opportunity. While there are risks associated with the success of its product, the company's valuation and financials suggest a positive outlook for investors.

Bears say

Kyverna Therapeutics is facing significant challenges in its development of cell therapies for autoimmune diseases, with limited financial resources and a narrow focus on just two product candidates. The company's high reliance on KYV-101 and KYV-201 makes it vulnerable to any setbacks or failures in their development, which could negatively impact its overall growth potential and stock performance. Additionally, the company's financial statements show increasing losses and declining revenue, suggesting potential struggles in commercializing its products in the future.

KYTX has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kyverna Therapeutics Inc (KYTX) Forecast

Analysts have given KYTX a Buy based on their latest research and market trends.

According to 4 analysts, KYTX has a Buy consensus rating as of Jun 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kyverna Therapeutics Inc (KYTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.